{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:07Z","timestamp":1792788007246,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science and Technology program of Jinhua Science and Technology Bureau","award":["2024-4-264"],"award-info":[{"award-number":["2024-4-264"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03839-6","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:00:38Z","timestamp":1747893638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review"],"prefix":"10.1186","volume":"23","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"3839_CR1","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","volume":"20","author":"K Mardinian","year":"2021","unstructured":"Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. SMARCA4: implications of an altered Chromatin-Remodeling gene for Cancer development and therapy. Mol Cancer Ther. 2021;20:2341\u201351.","journal-title":"Mol Cancer Ther"},{"key":"3839_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","volume":"15","author":"N Rekhtman","year":"2020","unstructured":"Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, et al. SMARCA4-Deficient thoracic sarcomatoid tumors represent primarily Smoking-Related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15:231\u201347.","journal-title":"J Thorac Oncol"},{"key":"3839_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/PAS.0000000000001188","volume":"43","author":"R Perret","year":"2019","unstructured":"Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, et al. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol. 2019;43:455\u201365.","journal-title":"Am J Surg Pathol"},{"key":"3839_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17:362\u201387.","journal-title":"J Thorac Oncol"},{"key":"3839_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/cncy.22581","volume":"130","author":"T Sun","year":"2022","unstructured":"Sun T, Gilani SM, Podany P, Harigopal M, Zhong M, Wang H. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features. Cancer Cytopathol. 2022;130:620\u20139.","journal-title":"Cancer Cytopathol"},{"key":"3839_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1053\/j.semdp.2020.12.002","volume":"38","author":"C Sesboue","year":"2021","unstructured":"Sesboue C, Le Loarer F. SWI\/SNF-deficient thoraco-pulmonary neoplasms. Semin Diagn Pathol. 2021;38:183\u201394.","journal-title":"Semin Diagn Pathol"},{"key":"3839_CR7","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung Cancer. Clin Cancer Res. 2020;26:5701\u20138.","journal-title":"Clin Cancer Res"},{"key":"3839_CR8","first-page":"560","volume":"63","author":"DN Reisman","year":"2003","unstructured":"Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1\/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 2003;63:560\u20136.","journal-title":"Cancer Res"},{"key":"3839_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cas.12065","volume":"104","author":"D Matsubara","year":"2013","unstructured":"Matsubara D, Kishaba Y, Ishikawa S, Sakatani T, Oguni S, Tamura T, et al. Lung cancer with loss of BRG1\/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci. 2013;104:266\u201373.","journal-title":"Cancer Sci"},{"key":"3839_CR10","doi-asserted-by":"publisher","first-page":"e16923","DOI":"10.7717\/peerj.16923","volume":"12","author":"P Zhou","year":"2024","unstructured":"Zhou P, Fu Y, Tang Y, Jiang L, Wang W. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor. PeerJ. 2024;12:e16923.","journal-title":"PeerJ"},{"key":"3839_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-012414-040445","volume":"10","author":"J Masliah-Planchon","year":"2015","unstructured":"Masliah-Planchon J, Bi\u00e8che I, Guinebreti\u00e8re J-M, Bourdeaut F, Delattre O. SWI\/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 2015;10:145\u201371.","journal-title":"Annu Rev Pathol"},{"key":"3839_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","volume":"175","author":"N Mashtalir","year":"2018","unstructured":"Mashtalir N, D\u2019Avino AR, Michel BC, Luo J, Pan J, Otto JE, et al. Modular organization and assembly of SWI\/SNF family chromatin remodeling complexes. Cell. 2018;175:1272\u2013e128820.","journal-title":"Cell"},{"key":"3839_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/PAS.0b013e3182196a39","volume":"35","author":"M Hasselblatt","year":"2011","unstructured":"Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid\/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 2011;35:933\u20135.","journal-title":"Am J Surg Pathol"},{"key":"3839_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ajhg.2010.01.013","volume":"86","author":"R Schneppenheim","year":"2010","unstructured":"Schneppenheim R, Fr\u00fchwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al. Germline nonsense mutation and somatic inactivation of SMARCA4\/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010;86:279\u201384.","journal-title":"Am J Hum Genet"},{"key":"3839_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/modpathol.2017.11","volume":"30","author":"A Yoshida","year":"2017","unstructured":"Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 2017;30:797\u2013809.","journal-title":"Mod Pathol"},{"key":"3839_CR16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/modpathol.2017.61","volume":"30","author":"JL Sauter","year":"2017","unstructured":"Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol. 2017;30:1422\u201332.","journal-title":"Mod Pathol"},{"key":"3839_CR17","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/ng.3399","volume":"47","author":"F Le Loarer","year":"2015","unstructured":"Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47:1200\u20135.","journal-title":"Nat Genet"},{"key":"3839_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1066896919865944","volume":"28","author":"BD Stewart","year":"2020","unstructured":"Stewart BD, Kaye F, Machuca T, Mehta HJ, Mohammed T-L, Newsom KJ, et al. SMARCA4-Deficient thoracic sarcoma: A case report and review of literature. Int J Surg Pathol. 2020;28:102\u20138.","journal-title":"Int J Surg Pathol"},{"key":"3839_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jtho.2020.01.002","volume":"15","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack I, Schrock AB, Kem M, Jessop N, Lee J, Ali SM, et al. Clinicopathologic characteristics of BRG1-Deficient NSCLC. J Thorac Oncol. 2020;15:766\u201376.","journal-title":"J Thorac Oncol"},{"key":"3839_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00428-020-03011-3","volume":"478","author":"K Chatzopoulos","year":"2021","unstructured":"Chatzopoulos K, Boland JM. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. Virchows Arch. 2021;478:21\u201330.","journal-title":"Virchows Arch"},{"key":"3839_CR21","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/1078-0432.CCR-15-1468","volume":"22","author":"EH Bell","year":"2016","unstructured":"Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, et al. SMARCA4\/BRG1 is a novel prognostic biomarker predictive of Cisplatin-Based chemotherapy outcomes in resected Non-Small cell lung Cancer. Clin Cancer Res. 2016;22:2396\u2013404.","journal-title":"Clin Cancer Res"},{"key":"3839_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00428-017-2148-5","volume":"471","author":"A Agaimy","year":"2017","unstructured":"Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartmann A, Haller F. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg\/CK7pos\/HepPar-1pos immunophenotype. Virchows Arch. 2017;471:599\u2013609.","journal-title":"Virchows Arch"},{"key":"3839_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1158\/2159-8290.CD-21-0248","volume":"12","author":"CP Concepcion","year":"2022","unstructured":"Concepcion CP, Ma S, LaFave LM, Bhutkar A, Liu M, DeAngelo LP, et al. Smarca4 inactivation promotes Lineage-Specific transformation and early metastatic features in the lung. Cancer Discov. 2022;12:562\u201385.","journal-title":"Cancer Discov"},{"key":"3839_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5858\/arpa.2019-0633-OA","volume":"145","author":"A Nambirajan","year":"2021","unstructured":"Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S, Jain D. SMARCA4\/BRG1-Deficient Non-Small cell lung carcinomas: A case series and review of the literature. Arch Pathol Lab Med. 2021;145:90\u20138.","journal-title":"Arch Pathol Lab Med"},{"key":"3839_CR25","doi-asserted-by":"publisher","first-page":"E1999","DOI":"10.1002\/humu.21415","volume":"32","author":"S Rodriguez-Nieto","year":"2011","unstructured":"Rodriguez-Nieto S, Ca\u00f1ada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, et al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1\/SMARCA4 in lung primary tumors. Hum Mutat. 2011;32:E1999\u20132017.","journal-title":"Hum Mutat"},{"key":"3839_CR26","doi-asserted-by":"crossref","unstructured":"Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4\/BRG1, in lung tumors. Genes Chromosom Cancer. 2004;41:170\u20137.","DOI":"10.1002\/gcc.20068"},{"key":"3839_CR27","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1200\/JCO.2014.59.2444","volume":"33","author":"LH Araujo","year":"2015","unstructured":"Araujo LH, Timmers C, Bell EH, Shilo K, Lammers PE, Zhao W, et al. Genomic characterization of Non-Small-Cell lung Cancer in African Americans by targeted massively parallel sequencing. J Clin Oncol. 2015;33:1966\u201373.","journal-title":"J Clin Oncol"},{"key":"3839_CR28","doi-asserted-by":"publisher","first-page":"216022","DOI":"10.1016\/j.canlet.2022.216022","volume":"554","author":"Y Tian","year":"2023","unstructured":"Tian Y, Xu L, Li X, Li H, Zhao M. SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Lett. 2023;554:216022.","journal-title":"Cancer Lett"},{"key":"3839_CR29","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1038\/s41467-020-19402-8","volume":"11","author":"TM Fernando","year":"2020","unstructured":"Fernando TM, Piskol R, Bainer R, Sokol ES, Trabucco SE, Zhang Q, et al. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. Nat Commun. 2020;11:5551.","journal-title":"Nat Commun"},{"key":"3839_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.yexcr.2012.06.011","volume":"318","author":"A Kothandapani","year":"2012","unstructured":"Kothandapani A, Gopalakrishnan K, Kahali B, Reisman D, Patrick SM. Downregulation of SWI\/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity. Exp Cell Res. 2012;318:1973\u201386.","journal-title":"Exp Cell Res"},{"key":"3839_CR31","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/0008-5472.CAN-20-1744","volume":"80","author":"M Gupta","year":"2020","unstructured":"Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, et al. BRG1 loss predisposes lung cancers to replicative stress and ATR dependency. Cancer Res. 2020;80:3841\u201354.","journal-title":"Cancer Res"},{"key":"3839_CR32","doi-asserted-by":"publisher","first-page":"e00667","DOI":"10.1002\/rcr2.667","volume":"8","author":"Y Chiba","year":"2020","unstructured":"Chiba Y, Kawanami T, Yamasaki K, Uchimura K, Matsuyama A, Yatera K. Hyper-progressive disease after immune checkpoint inhibitor in SMARCA4-deficient small-cell lung carcinoma. Respirol Case Rep. 2020;8:e00667.","journal-title":"Respirol Case Rep"},{"key":"3839_CR33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/1759-7714.13070","volume":"10","author":"T Naito","year":"2019","unstructured":"Naito T, Umemura S, Nakamura H, Zenke Y, Udagawa H, Kirita K, et al. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report. Thorac Cancer. 2019;10:1285\u20138.","journal-title":"Thorac Cancer"},{"key":"3839_CR34","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1038\/s41467-021-24618-3","volume":"12","author":"OA Romero","year":"2021","unstructured":"Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, et al. SMARCA4 deficient tumours are vulnerable to KDM6A\/UTX and KDM6B\/JMJD3 Blockade. Nat Commun. 2021;12:4319.","journal-title":"Nat Commun"},{"key":"3839_CR35","doi-asserted-by":"publisher","first-page":"14098","DOI":"10.1038\/ncomms14098","volume":"8","author":"V Tagal","year":"2017","unstructured":"Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.","journal-title":"Nat Commun"},{"key":"3839_CR36","doi-asserted-by":"publisher","first-page":"zcaa005","DOI":"10.1093\/narcan\/zcaa005","volume":"2","author":"K Kurashima","year":"2020","unstructured":"Kurashima K, Kashiwagi H, Shimomura I, Suzuki A, Takeshita F, Mazevet M, et al. SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR Inhibition in lung adenocarcinoma. NAR Cancer. 2020;2:zcaa005.","journal-title":"NAR Cancer"},{"key":"3839_CR37","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"3839_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"3839_CR39","doi-asserted-by":"publisher","first-page":"103472","DOI":"10.1016\/j.esmoop.2024.103472","volume":"9","author":"L-L Pang","year":"2024","unstructured":"Pang L-L, Zhou H-Q, Zhang Y-X, Zhuang W-T, Pang F, Chen L-J, et al. SWI\/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors\u2019 therapeutic implication. ESMO Open. 2024;9:103472.","journal-title":"ESMO Open"},{"key":"3839_CR40","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"Z-Y Dong","year":"2017","unstructured":"Dong Z-Y, Zhong W-Z, Zhang X-C, Su J, Xie Z, Liu S-Y, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 Blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23:3012\u201324.","journal-title":"Clin Cancer Res"},{"key":"3839_CR41","doi-asserted-by":"publisher","first-page":"100832","DOI":"10.1016\/j.neo.2022.100832","volume":"32","author":"E-M Talvitie","year":"2022","unstructured":"Talvitie E-M, Liljeroos L, Vilhonen H, Orte K, Leivo I, Kallajoki M, et al. Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis. Neoplasia. 2022;32:100832.","journal-title":"Neoplasia"},{"key":"3839_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.anndiagpath.2016.10.006","volume":"26","author":"E Herpel","year":"2017","unstructured":"Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, et al. SMARCA4 and SMARCA2 deficiency in non\u2013small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. Annals Diagn Pathol. 2017;26:47\u201351.","journal-title":"Annals Diagn Pathol"},{"key":"3839_CR43","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1158\/1078-0432.CCR-03-0489","volume":"10","author":"J Fukuoka","year":"2004","unstructured":"Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, et al. Chromatin remodeling factors and BRM\/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004;10:4314\u201324.","journal-title":"Clin Cancer Res"},{"key":"3839_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000510323","volume":"65","author":"A Nambirajan","year":"2021","unstructured":"Nambirajan A, Dutta R, Malik PS, Bubendorf L, Jain D. Cytology of SMARCA4-Deficient thoracic neoplasms: comparative analysis of SMARCA4-Deficient Non-Small cell lung carcinomas and SMARCA4-Deficient thoracic sarcomas. Acta Cytol. 2021;65:67\u201374.","journal-title":"Acta Cytol"},{"key":"3839_CR45","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/j.jtho.2021.01.1613","volume":"16","author":"J Metovic","year":"2021","unstructured":"Metovic J, Bianchi F, Barella M, Papotti M, Pelosi G. SMARCA2 deficiency while preserving SMARCA4 and SMARCB1 in lung neuroendocrine carcinomas. J Thorac Oncol. 2021;16:e32\u20135.","journal-title":"J Thorac Oncol"},{"key":"3839_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41467-019-08380-1","volume":"10","author":"Y Xue","year":"2019","unstructured":"Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, et al. SMARCA4 loss is synthetic lethal with CDK4\/6 Inhibition in non-small cell lung cancer. Nat Commun. 2019;10:557.","journal-title":"Nat Commun"},{"key":"3839_CR47","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1038\/sj.onc.1210514","volume":"26","author":"S Glaros","year":"2007","unstructured":"Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic Silencing of BRM: implications for clinical targeted therapy. Oncogene. 2007;26:7058\u201366.","journal-title":"Oncogene"},{"key":"3839_CR48","doi-asserted-by":"publisher","first-page":"10155","DOI":"10.1021\/acs.jmedchem.8b01318","volume":"61","author":"JPN Papillon","year":"2018","unstructured":"Papillon JPN, Nakajima K, Adair CD, Hempel J, Jouk AO, Karki RG, et al. Discovery of orally active inhibitors of Brahma homolog (BRM)\/SMARCA2 ATPase activity for the treatment of Brahma related gene 1 (BRG1)\/SMARCA4-Mutant cancers. J Med Chem. 2018;61:10155\u201372.","journal-title":"J Med Chem"},{"key":"3839_CR49","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1073\/pnas.1316793111","volume":"111","author":"GR Hoffman","year":"2014","unstructured":"Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, et al. Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A. 2014;111:3128\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3839_CR50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/MCB.01372-13","volume":"34","author":"BG Wilson","year":"2014","unstructured":"Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014;34:1136\u201344.","journal-title":"Mol Cell Biol"},{"key":"3839_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bbrc.2018.09.009","volume":"508","author":"F Rago","year":"2019","unstructured":"Rago F, DiMare MT, Elliott G, Ruddy DA, Sovath S, Kerr G, et al. Degron mediated BRM\/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1\/SMARCA4-mutant cancers. Biochem Biophys Res Commun. 2019;508:109\u201316.","journal-title":"Biochem Biophys Res Commun"},{"key":"3839_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/13543776.2024.2355258","volume":"34","author":"ECY Lee","year":"2024","unstructured":"Lee ECY, Reichl KD, Gopalsamy A. Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors \u2013 a review of patent literature from 2019\u2013June 2023. Expert Opin Ther Pat. 2024;34:211\u201329.","journal-title":"Expert Opin Ther Pat"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03839-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03839-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03839-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:04:29Z","timestamp":1747897469000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03839-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03839-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by the institutional ethics review board of the Fourth Affiliated Hospital, Zhejiang University School of Medicine (K2025006) and conducted in accordance with the principles of the World Medical Association\u2019s Declaration of Helsinki \u201cEthical Principles for Medical Research Involving Human Beings.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from the patient to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"198"}}